SPRB — Spruce Biosciences Income Statement
0.000.00%
Last trade - 00:00- $89.27m
- $79.14m
- $4.91m
Annual income statement for Spruce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 10.1 | 4.91 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 29.4 | 42.1 | 47.3 | 62.1 | 61.1 |
| Operating Profit | -29.4 | -42.1 | -47.3 | -52 | -56.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.5 | -42.3 | -46.2 | -47.9 | -53 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -29.5 | -42.3 | -46.2 | -47.9 | -53 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -29.5 | -42.3 | -46.2 | -47.9 | -53 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -29.5 | -42.3 | -46.2 | -47.9 | -53 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -99.5 | -136 | -147 | -93.3 | -96.4 |